Iktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms. The company was founded in 2016 and headquartered in Paris, France. It has raised $16.3M in series a funding, with backing from M Ventures, Debiopharm, Omnes Capital. The company operates in the HealthTech - Life Sciences Tech, Life Sciences - Life Sciences Tech, Native AI - Artificial Intelligence space. Its offerings span Oncology - Drugs - Pan Cancer and Metabolic Diseases - Drugs - Obesity.
Iktos
Series AIktos offers artificial intelligence for new drug design. The company is using artificial intelligence technology for ligand-based de novo drug design and focusing on multiparametric optimization (MPO). Their platform can design new, druggable and synthesizable molecules according to particular criteria. Their technology is based on deep learning algorithms. The company was founded in 2016 and headquartered in…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based,
Oncology > Drugs > Pan Cancer,
Metabolic Diseases > Drugs > Obesity,
Obesity > Drugs,
Immunology > Drugs > Diversified
Founders & team highlights
Serial Founder
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Explore HealthTech investors — funds that write checks in this sector.